<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752115</url>
  </required_header>
  <id_info>
    <org_study_id>Hamamatsu 18-66</org_study_id>
    <nct_id>NCT00752115</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>Randomized Phase II Study of Combination Chemotherapy With Sildenafil Plus Carboplatin and Weekly Paclitaxel in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamamatsu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamamatsu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of combination chemotherapy of sildenafil plus carboplatin and weekly taxol with
      carboplatin and weekly taxol in patients with previously untreated advanced non-small cell
      lung cancer. The study hypothesis is that sildenafil may improve the distribution and
      efficacy of cytotoxic anticancer agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sildenafil is one of selective phosphodiesterase type 5 inhibitors. It is used to block the
      degradative action of phosphodiesterase type 5 on cyclic GMP in the smooth muscle cells
      lining the blood vessels, which leads to smooth muscle relaxation in blood vessels and
      increases blood flow. Because phosphodiesterase type 5 is also present in the arterial wall
      smooth muscle within the lungs, phosphodiesterase type 5 inhibitors is also used for the
      treatment of pulmonary hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>three-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>three-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil plus carboplatin and weekly paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>carboplatin and weekly paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>50mg, day1,8 and 15 in each cycle</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 tab, day 1,8 and 15 in each cycle.</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel (taxol)</intervention_name>
    <description>paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>P</arm_group_label>
    <other_name>taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin (palaplatin)</intervention_name>
    <description>carboplatin; AUC=6 on day 1, every 28 days</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>P</arm_group_label>
    <other_name>palaplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of histologically confirmed stage IIIB or IV non-small cell lung cancer

          -  Good performance status (ECOG 0-1)

          -  No previous treatment

          -  Adequate bone marrow, liver and renal functions

          -  Must be able to swallow tablets

          -  Provided written informed consent

        Exclusion Criteria:

          -  Severe complications or a concomitant malignancy

          -  Contraindicated sildenafil, carboplatin or taxol

          -  Inappropriate patients for entry to this study, judged by the physicians
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kingo Chida, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hamamatsu University School of Medicien Institution Review Board</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamamatsu University School of Medicine</name>
      <address>
        <city>Hamamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2008</study_first_posted>
  <last_update_submitted>September 5, 2011</last_update_submitted>
  <last_update_submitted_qc>September 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamamatsu University</investigator_affiliation>
    <investigator_full_name>Naoki Inui</investigator_full_name>
    <investigator_title>Department of Respiratory Medicine</investigator_title>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>previously untreated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

